Additional Digestive Disease Week data highlight effects of AMITIZA in
patients with IBS-C
SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists.
"IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists," said William D. Chey, M.D., primary investigator of the study, University of Michigan Health System. "These data are important because they show that in studies, AMITIZA has demonstrated the ability to improve the overall symptoms reported by patients with IBS-C."
AMITIZA 8 mcg was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2008 for the treatment of IBS-C in women 18 years of age and older, and has been approved since 2006 at a 24 mcg dose for the treatment of Chronic Idiopathic Constipation in adults. These data were among others presented at DDW 2008 that evaluated the effect of AMITIZA for IBS-C.
"AMITIZA is the first ClC-2 channel activator and the only widely available FDA-approved agent for the treatment of IBS-C in adult women in the United States. AMITIZA could provide overall symptom relief for the millions of appropriate patients in the U.S. who suffer from this condition," said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals (Nasdaq: SCMP). "We are pleased with the body of data on AMITIZA presented at DDW this year. Additional data presented at this meeting may help physicians better understand how to treat their patients with IBS-C."
"AMITIZA makes it possible for appropriate patients to receive a widely available FDA-approved treatment for their IBS-C," said Charles Baum, M.D., gastroenterologist and executive medical director, Gastroenterology and Internal Medicine, Takeda Pharmaceuticals North America, Inc.
Approximately 58 million Americans have Irritable Bowel Syndrome (IBS), and IBS-C accounts for approximately one-third of these cases. IBS-C is a chronic disorder characterized by abdominal discomfort or pain and changes in bowel habits including symptoms of constipation.
AMITIZA was developed by Sucampo Pharmaceuticals and is co-marketed in the U.S. by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.
About Irritable Bowel Syndrome with Constipation (IBS-C)
IBS is a disorder characterized by symptoms including recurrent
abdominal discomfort or pain, bloating, and changes of bowel habits such as
constipation and/or diarrhea. There are three main types of IBS: IBS with
constipation (IBS-C), IBS with diarrhea (IBS-D), and IBS with mixed
constipation and diarrhea (IBS-M). In IBS-C, symptoms are present for at
least 12 weeks (not necessarily consecutive) over a 12-month period.
Although people with IBS-C report many of the symptoms associated with
constipation, the presence of abdominal discomfort or pain is what
differentiates IBS-C from chronic constipation. IBS is approximately two to
two-and-a-half times more prevalent in women than men.
Number Abstract Title Type/Date/Time
157 What Symptoms Drive Global Symptom Oral; Sunday, May
Improvement with Lubiprostone in 18, 2008 at 3:00pm
Patients with Irritable Bowel Syndrome PDT
and Constipation: Data from Two
Multicenter, Randomized, Placebo-
S1272 Lubiprostone is Effective and Well Poster; Sunday, May
Tolerated Through 48 Weeks of 18, 2008 from 8am-
Treatment in Adults with Irritable 5pm PDT; Poster
Bowel Syndrome and Constipation presentation from
T1036 Health-Related Quality of Life in Poster; Tuesday,
Adults with Irritable Bowel Syndrome May 20, 2008 from
with Constipation: Results of a 8am-5pm PDT; Poster
Combined Analysis of Two Phase 3 presentation from
Studies with Lubiprostone 12pm-2pm PDT
M1706 Discontinuation of Lubiprostone Poster; Monday, May
Treatment for Irritable Bowel Syndrome 19, 2008 from 8am-
with Constipation is Not Associated 5pm PDT; Poster
with Symptom Increase or Recurrence: presentation from
Results from a randomized withdrawal 12pm-2pm PDT
Number Abstract Title Type/Date/Time
T1029 Development of an Instrument to Assess Poster; Tuesday,
Treatment Satisfaction in Patients May 20, 2008 from
with Chronic Constipation 8am-5pm PDT; Poster
T1030 Similarities between Constipation with Poster; Tuesday,
and without Irritable Bowel Syndrome May 20, 2008 from
in a California Medicaid (Medi-Cal) 8am-5pm PDT; Poster
population: Costs trends by category presentation from
in the 12 months after diagnosis from 12pm-2pm PDT
1997 to 2002
808 Direct Medical Costs Associated with Oral; Tuesday, May
Constipation from Childhood to Early 20, 2008 from 4pm-
Adulthood: A Birth Cohort Study 5:30pm PDT;
T1876 Lubiprostone Activation of Cl- Poster; Tuesday,
Currents Does Not Involve Ca2+, cAMP, May 20, 2008 from
or PKA 8am-5pm PDT; Poster
T1877 ClC-2-Targeted siRNA Eliminates Poster; Tuesday,
Lubiprostone Activation of Cl- May 20, 2008 from
Currents in T84 Cells 8am-5pm PDT; Poster
T1081 Effect of Lubiprostone on Duodenal Poster; Tuesday,
Mucosal Bicarbonate Secretion May 20, 2008 from
8am-5pm PDT; Poster
844 Lubiprostone Reverses the Inhibitory Oral; Tuesday, May
Action of Morphine on Mucosal 20, 2008 from 4pm-
Secretion in the Human Jejunum 5:30pm PDT;
T1380 Lubiprostone Enhances Histamine H2 Poster; Tuesday,
Receptor-Mediated Cyclical Chloride May 20, 2008 from
Secretion in the Guinea Pig Colon 8am-5pm PDT; Poster
About AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation and IBS-C Indication
AMITIZA(R) (lubiprostone) is indicated for the treatment of Chronic Idiopathic Constipation (24 mcg) in adults and for Irritable Bowel Syndrome with Constipation (8 mcg) in women > 18 years old.
Important Safety Information
AMITIZA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating physician to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.
The safety of AMITIZA in pregnancy has not been evaluated in humans. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their physician.
AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe.
Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician.
In clinical trials of AMITIZA (24 mcg) in patients with Chronic Idiopathic Constipation, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).
In clinical trials of AMITIZA (8 mcg) in patients with Irritable Bowel Syndrome with Constipation, the most common adverse reactions (incidence > 4%) were nausea (8%), diarrhea (7%), and abdominal pain (5%).
Please see complete Prescribing Information at http://www.amitiza.com.
AMITIZA is co-marketed by Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, Md., focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.
Sucampo Pharmaceuticals is marketing AMITIZA(R) (lubiprostone) in the U.S. for Chronic Idiopathic Constipation in adults and Irritable Bowel Syndrome with Constipation in women 18 years of age and older and is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly-owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit http://www.sucampo.com
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, TPNA currently markets products for diabetes, insomnia, wakefulness and gastroenterology. The company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. TPNA is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com
About Digestive Disease Week (DDW)
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the
Alimentary Tract, DDW takes place May 17-22, 2008, at the San Diego Convention Center, San Diego, CA. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org
|SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals,|
Copyright©2008 PR Newswire.
All rights reserved